PFN1 Antibody

What is PFN1 and why is it important in cellular research?

Profilin-1 (PFN1) is a ubiquitously expressed actin monomer-binding protein belonging to the profilin family. It serves as a key regulator of actin polymerization in a concentration-dependent manner—inhibiting polymerization at high concentrations while enhancing it at low concentrations . This dynamic regulatory ability makes it critical for controlling cytoskeletal structure, which in turn influences cell shape, motility, and internal movement . PFN1's fundamental role in actin dynamics positions it as an important target for research into cellular processes dependent on cytoskeletal function, including cell division, migration, and morphological changes . Additionally, its connections to neurodegenerative diseases like amyotrophic lateral sclerosis (ALS) and its potential tumor-suppressive activities in breast cancer have elevated its significance in biomedical research .

What applications are PFN1 antibodies typically used for in laboratory research?

PFN1 antibodies are employed across multiple experimental applications in research settings:

• Western Blotting (WB): Used to detect and quantify PFN1 protein levels in cell or tissue lysates. This application allows researchers to compare expression levels across different experimental conditions or between normal and pathological states .

• Immunoprecipitation (IP): Enables isolation of PFN1 protein complexes to study protein-protein interactions and post-translational modifications that may regulate its function .

• Immunofluorescence (IF): Facilitates visualization of PFN1's subcellular localization and potential co-localization with interaction partners such as actin or other cytoskeletal components .

• Immunohistochemistry (IHC): Allows detection of PFN1 in tissue sections, providing insights into its expression patterns in different cell types and under various physiological or pathological conditions .

• Flow Cytometry (FACS): Used to quantify PFN1 levels in individual cells within heterogeneous populations .

What species reactivity is available for PFN1 antibodies?

PFN1 antibodies are available with reactivity against multiple species, reflecting the high conservation of this protein across evolutionary lineages. Based on the available information, researchers can select antibodies with reactivity to:

• Human

• Mouse

• Rat

• Cow

• Guinea Pig

• Horse

• Zebrafish (Danio rerio)

• Monkey

• Dog

When selecting a PFN1 antibody, it's important to verify the predicted reactivity for your species of interest. For example, the antibody described in search result shows predicted reactivity as follows: Human (100%), Mouse (100%), Rat (100%), Cow (100%), Guinea Pig (100%), Horse (100%), and Zebrafish (91%) . This high sequence homology across species enables cross-reactivity of many PFN1 antibodies, offering flexibility in experimental design across different model organisms.

What are the standard validation methods for PFN1 antibodies?

Validation of PFN1 antibodies follows standardized experimental protocols that typically involve comparative analysis between wild-type and knockout systems:

• Knockout Cell Validation: Comparing antibody signals between wild-type (WT) cells and PFN1 knockout (KO) cells. The absence of signal in KO cells demonstrates antibody specificity .

• Western Blot Validation: Running WT and KO cell lysates side-by-side to confirm the absence of bands at the expected molecular weight (~15 kDa for PFN1) in KO samples .

• Immunofluorescence Validation: Performing parallel staining in WT and KO cells to verify the specificity of immunofluorescent signals .

• Overexpression Systems: Confirming increased signal intensity in cells overexpressing PFN1 compared to control cells .

• Recombinant Protein Controls: Using purified recombinant PFN1 protein as a positive control to verify antibody recognition specificity and to generate standard curves for quantification .

The HAP1 cell line has been identified as expressing sufficient levels of PFN1 for validation experiments, with DepMap transcriptomics data showing PFN1 expression above 2.5 log2 (TPM+1), which serves as a suitable cut-off for antibody validation studies .

How can researchers determine the appropriate concentration of PFN1 antibodies for specific experimental applications?

Determining optimal antibody concentrations requires methodical titration approaches to balance signal strength against background noise:

• Western Blot Optimization: Begin with a concentration range between 0.1-5 μg/mL and perform serial dilutions. The antibody documented in search result demonstrates effective detection at 1 μg/mL in HeLa and HEK-293 cell lysates . For PFN1 detection, it's advisable to run a titration series (e.g., 0.1, 0.5, 1, 2, 5 μg/mL) and select the lowest concentration that yields a clear, specific band at approximately 15 kDa with minimal background.

• Immunofluorescence Titration: Start with dilutions ranging from 1:100 to 1:2000. The optimal dilution should provide distinct subcellular localization patterns consistent with PFN1's known distribution while minimizing non-specific background. For paraffin-embedded tissues, a 1:1000 dilution has been reported as effective for some PFN1 antibodies .

• Immunoprecipitation Calibration: For IP applications, antibody amounts typically range from 1-5 μg per sample. Optimization should include testing multiple antibody concentrations against a fixed amount of lysate (typically 500-1000 μg of total protein).

• Positive and Negative Controls: Always include:

  • Positive control: Wild-type cells known to express PFN1

  • Negative control: PFN1 knockout cells

  • Isotype control: Non-specific antibody of the same isotype to assess background binding

• Signal-to-Noise Ratio Analysis: Calculate the ratio between specific signal intensity and background for each concentration tested, selecting the concentration that maximizes this ratio.

What strategies can be employed to address non-specific binding when using PFN1 antibodies?

Non-specific binding can compromise experimental results, particularly in sensitive applications. Several strategies can mitigate this issue:

• Blocking Optimization: Test different blocking agents (BSA, non-fat milk, normal serum, commercial blockers) at various concentrations (1-5%) and incubation times (30 minutes to overnight) to identify the most effective combination for reducing background while preserving specific signals.

• Antibody Format Selection: Compare the performance of different antibody formats. For example, monoclonal antibodies like clones 1D5, 2D2, and CL3524 may offer higher specificity than polyclonal alternatives when non-specific binding is problematic .

• Cross-Adsorption: Use pre-adsorption with cellular components from PFN1 knockout cells to remove antibodies that bind to non-target epitopes.

• Epitope-Specific Selection: Choose antibodies targeting distinct epitopes of PFN1:

  • N-terminal antibodies (aa 1-50)

  • Central region antibodies (aa 50-87)

  • C-terminal antibodies (aa 87-140)

• Detergent Optimization: Adjust detergent type and concentration in washing buffers. For PFN1 immunofluorescence, increasing Tween-20 concentration from 0.05% to 0.1% in PBS wash buffers can reduce cytoplasmic background while maintaining specific signals.

• Signal Validation: Confirm specificity through comparative analysis between wild-type and PFN1 knockout cells using standardized experimental protocols .

How can researchers differentiate between PFN1 and other profilin family members when using antibodies?

Distinguishing between profilin family members requires careful antibody selection and experimental design:

• Epitope Mapping: Select antibodies raised against regions with minimal sequence homology between profilin family members. The N-terminal and C-terminal regions typically show greater sequence divergence than the conserved actin-binding domains.

• Verification with Recombinant Proteins: Test antibody cross-reactivity against purified recombinant proteins of different profilin family members (PFN1, PFN2, PFN3, PFN4) through dot blot or Western blot analysis.

• Knockout Controls: Use cell lines with specific knockout of individual profilin family members to verify antibody specificity. The HAP1 PFN1 knockout cell line (catalog: HZGHC005831c016) has been validated for this purpose .

• Tissue-Specific Expression Analysis: Leverage the distinct expression patterns of profilin family members—PFN1 is ubiquitously expressed, while PFN2 is primarily neuronal, and PFN3/PFN4 are predominantly expressed in reproductive tissues—to help confirm antibody specificity in tissue samples.

• Western Blot Resolution: Though profilin family members have similar molecular weights, careful SDS-PAGE optimization using high-percentage gels (15-18%) can sometimes resolve the subtle differences in migration patterns between family members.

• Immunoprecipitation-Mass Spectrometry: When absolute certainty is required, immunoprecipitate with the PFN1 antibody followed by mass spectrometry analysis to confirm the identity of the captured protein.

What are the implications of PFN1 mutations in neurodegenerative disease research, and how can antibodies help study these mechanisms?

PFN1 mutations have been identified in familial amyotrophic lateral sclerosis (fALS) patients, placing it among cytoskeletal-related genes implicated in motor neuron degeneration . Antibody-based approaches are vital for investigating the pathogenic mechanisms:

• Mutation-Specific Studies: Antibodies can be used to compare wild-type and mutant PFN1 in terms of:

  • Expression levels and stability through quantitative Western blotting

  • Subcellular localization via immunofluorescence

  • Protein-protein interactions through co-immunoprecipitation

  • Aggregation propensity using detergent solubility fractionation followed by immunoblotting

• Mouse Model Analysis: PFN1 mutant mice carrying the G118V mutation display motor defects consistent with ALS pathology . Immunohistochemical analysis with PFN1 antibodies can reveal pathological features in motor neurons and other affected tissues.

• Cytoskeletal Dynamics: Since PFN1 directly affects cytoskeletal dynamics, antibodies can be used to:

  • Visualize alterations in actin organization in the presence of mutant PFN1

  • Assess co-localization with other cytoskeletal components like TUBA4, ALS2, KIF5A, and SPAST

  • Quantify changes in the ratio of filamentous to globular actin

• Pathological Aggregation: Immunofluorescence with PFN1 antibodies can detect protein aggregation, a common feature in neurodegenerative diseases. This can be combined with markers for stress granules, ubiquitin, or other ALS-associated proteins to characterize pathological inclusions.

• Therapeutic Development: Antibodies are essential tools for screening potential therapeutics targeting PFN1-related pathways, allowing quantification of effects on PFN1 expression, localization, and function.

How does PFN1 overexpression impact signaling pathways, and what antibody-based methods can be used to study these effects?

PFN1 overexpression has been shown to affect critical signaling pathways, particularly in cancer cells:

• AKT Signaling Inhibition: Even moderate PFN1 overexpression (1.65-fold) leads to significant reduction in AKT phosphorylation in MDA-MB-231 breast cancer cells . This can be studied using:

  • Phospho-specific AKT antibodies to detect changes in S473 and T308 phosphorylation sites

  • Antibodies against downstream targets like phospho-GSK-3β (S9) to assess functional consequences

  • Co-immunoprecipitation to investigate altered protein-protein interactions in the AKT pathway

• Phosphoinositide Regulation: PFN1 overexpression reduces PIP3 levels, affecting AKT membrane recruitment . This can be investigated using:

  • Immunofluorescence to visualize altered membrane localization of AKT following growth factor stimulation

  • Quantitative analysis of membrane-to-cytoplasm fluorescence intensity ratios (Imembrane/Icytoplasm)

  • PIP3-specific antibodies or biosensors to directly measure phosphoinositide levels

• PTEN Upregulation: PFN1 overexpression upregulates PTEN, a tumor suppressor that antagonizes PI3K/AKT signaling . This relationship can be studied using:

  • Western blot to quantify PTEN protein levels

  • qRT-PCR with PFN1 antibody-based chromatin immunoprecipitation (ChIP) to investigate transcriptional effects

  • Dual immunofluorescence to assess co-localization patterns

• Cell Cycle and Proliferation: Antibody-based flow cytometry can be used to correlate PFN1 expression levels with cell cycle progression markers.

• Tumor Suppression Mechanisms: The tumor-suppressive properties of PFN1 in breast cancer can be investigated using antibodies to track changes in:

  • Cell invasion markers

  • Apoptotic proteins

  • Epithelial-mesenchymal transition markers

What are the optimal sample preparation methods for PFN1 detection using antibodies?

Effective sample preparation is crucial for reliable PFN1 detection across different applications:

• Western Blot Sample Preparation:

  • Cell Lysis Buffer: RIPA buffer supplemented with protease inhibitors and phosphatase inhibitors is effective for extracting PFN1 from most cell types

  • Protein Quantification: BCA or Bradford assay to ensure equal loading

  • Sample Denaturation: Heat samples at 95°C for 5 minutes in Laemmli buffer with β-mercaptoethanol

  • Gel Percentage: Use 12-15% acrylamide gels for optimal resolution of the ~15 kDa PFN1 protein

  • Transfer Conditions: Semi-dry transfer at 15V for 1 hour or wet transfer at 100V for 1 hour using 0.2 μm PVDF membrane

• Immunofluorescence Sample Preparation:

  • Fixation: 4% paraformaldehyde for 15 minutes at room temperature preserves cytoskeletal structures

  • Permeabilization: 0.1% Triton X-100 for 10 minutes provides access to intracellular PFN1

  • Blocking: 5% normal serum (from the species of secondary antibody) for 1 hour

  • Antibody Incubation: Primary antibody dilution in blocking buffer overnight at 4°C followed by fluorophore-conjugated secondary antibody for 1 hour at room temperature

  • Counterstaining: DAPI for nucleus visualization and phalloidin for F-actin staining to assess co-localization

• Immunohistochemistry Sample Preparation:

  • Fixation: Formalin-fixed, paraffin-embedded (FFPE) tissues have been successfully used with PFN1 antibodies

  • Antigen Retrieval: Citrate buffer (pH 6.0) heat-induced epitope retrieval

  • Endogenous Peroxidase Blocking: 3% hydrogen peroxide for 10 minutes

  • Dilution: 1:1000 dilution has been effective for some PFN1 antibodies in FFPE kidney tissue

• Immunoprecipitation Sample Preparation:

  • Lysis Buffer: Non-denaturing lysis buffer (150 mM NaCl, 1% NP-40, 50 mM Tris pH 8.0) with protease inhibitors

  • Pre-Clearing: Incubate lysate with protein A/G beads to reduce non-specific binding

  • Antibody Binding: Incubate cleared lysate with PFN1 antibody overnight at 4°C

  • Bead Capture: Add protein A/G beads for 2-4 hours at 4°C

  • Washing: Multiple washes with decreasing salt concentration

  • Elution: Gentle elution with non-reducing sample buffer or specific peptide competition

What are the recommended protocols for quantifying PFN1 levels in cells and tissues?

Accurate quantification of PFN1 requires standardized protocols and appropriate controls:

• Western Blot Quantification:

  • Loading Controls: β-actin, GAPDH, or total protein staining (Ponceau S, SYPRO Ruby)

  • Standard Curve: Include recombinant PFN1 protein standards (5, 10, 25, 50, 100 ng) for absolute quantification

  • Densitometric Analysis: Use software like ImageJ to quantify band intensity relative to loading controls

  • Normalization: When comparing PFN1 levels, establish an accurate baseline using a calibration curve with known quantities of recombinant PFN1 as shown in figure 1B of search result

• Immunofluorescence Quantification:

  • Z-stack Acquisition: Collect multiple focal planes to capture total cellular PFN1

  • Standardized Exposure: Use identical acquisition parameters for all experimental conditions

  • Background Subtraction: Apply consistent background correction methods

  • Integrated Density Measurement: Quantify total fluorescence intensity within defined cellular regions

  • Single-Cell Analysis: Measure PFN1 levels in individual cells to account for heterogeneity

• Flow Cytometry Quantification:

  • Gating Strategy: Define populations based on forward/side scatter and viability markers

  • Fluorescence Calibration: Use calibration beads to convert arbitrary fluorescence units to molecules of equivalent soluble fluorochrome (MESF)

  • Median Fluorescence Intensity (MFI): Calculate relative PFN1 expression levels

  • Isotype Controls: Subtract background signal from specific signal

• ELISA-Based Quantification:

  • Standard Curve: Generate a standard curve using recombinant PFN1 protein

  • Sample Dilution Series: Ensure measurements fall within the linear range of the assay

  • Spike-in Recovery: Validate accuracy by adding known amounts of recombinant PFN1 to samples

  • Coefficient of Variation: Calculate to ensure assay precision

How can researchers effectively use PFN1 antibodies to study protein-protein interactions?

Investigating PFN1's interactions with binding partners requires specialized antibody-based techniques:

• Co-Immunoprecipitation (Co-IP):

  • Forward IP: Immunoprecipitate PFN1 and probe for interaction partners

  • Reverse IP: Immunoprecipitate suspected binding partners and probe for PFN1

  • Crosslinking: Consider mild crosslinking (e.g., DSP, formaldehyde) to stabilize transient interactions

  • Wash Stringency: Adjust salt and detergent concentrations to maintain specific interactions while reducing background

  • Elution Strategy: Use gentle elution methods (competitive peptide elution, low pH) to preserve interaction integrity

• Proximity Ligation Assay (PLA):

  • In Situ Detection: Visualize PFN1 interactions with actin or other partners directly in cells

  • Quantification: Count PLA spots per cell to measure interaction frequency

  • Distance Limitation: PLA detects proteins within 40 nm proximity, suitable for direct interactions

  • Controls: Include technical controls (single primary antibody) and biological controls (known non-interactors)

• Fluorescence Resonance Energy Transfer (FRET):

  • Antibody-Based FRET: Use fluorophore-conjugated primary or secondary antibodies against PFN1 and potential binding partners

  • Live-Cell Applications: For dynamics studies, combine with fluorescent protein-tagged constructs

  • Acceptor Photobleaching: Measure donor fluorescence increase after acceptor photobleaching to confirm interaction

  • Controls: Include positive controls (known interactors) and negative controls (non-interacting proteins)

• Immunofluorescence Co-localization:

  • Dual Staining: Combine PFN1 antibody with antibodies against suspected interaction partners

  • High-Resolution Imaging: Use confocal or super-resolution microscopy for precise co-localization analysis

  • Quantitative Co-localization: Calculate Pearson's correlation coefficient or Manders' overlap coefficient

  • Stimulus-Dependent Changes: Monitor co-localization changes in response to stimuli like growth factors

• Pull-Down Assays with Tagged Binding Partners:

  • GST-Tagged PFN1: Use to pull down interacting proteins from cell lysates

  • Validation: Confirm interactions by Western blot using specific antibodies

  • Competition Assays: Use excess untagged protein to demonstrate binding specificity

  • Mutational Analysis: Compare binding of wild-type and mutant PFN1 to identify critical interaction domains

What is the recommended experimental design for studying PFN1 in disease models using antibodies?

Investigating PFN1's role in diseases requires carefully designed experimental approaches:

• Neurodegenerative Disease Models:

  • ALS Patient Samples: Compare PFN1 expression, localization, and post-translational modifications in motor neurons from ALS patients versus controls using immunohistochemistry

  • PFN1 Mutant Mouse Models: Analyze the G118V mutation model using immunofluorescence to track PFN1 aggregation and cytoskeletal changes in motor neurons

  • iPSC-Derived Motor Neurons: Generate neurons from ALS patient-derived iPSCs and control individuals to study PFN1 dynamics using time-lapse imaging with fluorescently-labeled antibodies

• Cancer Models:

  • Tumor Microarray Analysis: Use immunohistochemistry to compare PFN1 expression across cancer stages and types

  • Cell Line Panels: Systematic Western blot analysis of PFN1 expression across cancer cell lines with different metastatic potential

  • Xenograft Models: Manipulate PFN1 expression and monitor tumor growth, analyzing samples with immunohistochemistry

  • Signaling Pathway Analysis: Use phospho-specific antibodies to investigate the relationship between PFN1 and AKT pathway activation as described in search result

• Experimental Controls:

  • Genetic Models: Compare wild-type, heterozygous, and homozygous knockout animals

  • Rescue Experiments: Reintroduce wild-type or mutant PFN1 in knockout backgrounds

  • Dose-Response: Create cell lines with different levels of PFN1 overexpression (e.g., 1.65-fold as in search result )

  • Tissue-Specific Analysis: Compare PFN1 expression and localization across affected and unaffected tissues

• Temporal Dynamics:

  • Disease Progression: Track PFN1 changes at different disease stages

  • Treatment Response: Monitor PFN1 alterations during therapeutic interventions

  • Aging Studies: Compare PFN1 expression and function in young versus aged samples

  • Stress Response: Analyze acute versus chronic stress effects on PFN1 using stress-specific markers alongside PFN1 antibodies

What antibody formats are available for PFN1 detection, and how should researchers select between them?

PFN1 antibodies are available in various formats, each with specific advantages for different applications:

Selection criteria should include:

• Application Compatibility: Based on validation data, certain antibodies perform better in specific applications. For example, the monoclonal antibody CL3524 has been validated for both Western blot and IHC-P applications .

• Epitope Accessibility: Consider whether the target epitope might be masked in your experimental system. N-terminal antibodies (like ABIN2783306) and C-terminal antibodies may access different epitopes depending on protein conformation or interaction status .

• Species Cross-Reactivity: Verify compatibility with your model system. Some antibodies offer broad cross-reactivity (human, mouse, rat, cow, guinea pig, horse, zebrafish) , while others have more limited species reactivity.

• Validation Evidence: Prioritize antibodies with comprehensive validation, especially those tested in knockout systems as described in search result .

• Signal-to-Noise Ratio: Polyclonal antibodies often provide stronger signals but may have higher background, while monoclonals typically offer cleaner results with potentially lower sensitivity.

What are common challenges in PFN1 antibody experiments and how can they be addressed?

Researchers may encounter several technical challenges when working with PFN1 antibodies:

• Cross-Reactivity with Other Profilin Family Members:

  • Challenge: Antibodies may detect multiple profilin isoforms.

  • Solution: Use antibodies targeting unique regions; validate with recombinant proteins of each isoform; confirm with knockout controls.

• Inconsistent Western Blot Results:

  • Challenge: Variable band intensity or multiple bands.

  • Solution: Optimize protein extraction (RIPA buffer with protease inhibitors); use fresh samples; run 15% gels for better resolution of the small ~15 kDa protein; include positive controls (recombinant PFN1) and negative controls (PFN1 KO cells) .

• High Background in Immunofluorescence:

  • Challenge: Non-specific staining obscuring true signal.

  • Solution: Increase blocking stringency (5% serum, 1% BSA, 0.1% Triton X-100); optimize antibody concentrations through titration; include additional wash steps; use PFN1 KO cells as negative controls .

• Epitope Masking:

  • Challenge: PFN1's interactions with actin and other proteins may mask antibody binding sites.

  • Solution: Test antibodies targeting different epitopes; optimize fixation conditions; consider native versus denatured detection methods.

• Quantification Difficulties:

  • Challenge: Accurate measurement of PFN1 levels.

  • Solution: Include standard curves with recombinant protein; use appropriate loading controls; perform densitometric analysis of multiple technical and biological replicates .

• Detecting Low Expression Levels:

  • Challenge: Weak signal in certain cell types or conditions.

  • Solution: Use signal amplification methods (HRP-conjugated polymers, tyramide signal amplification); increase exposure times while monitoring background; concentrate proteins through immunoprecipitation before detection.

How can researchers validate the specificity of their PFN1 antibody-based experimental results?

Rigorous validation is essential for ensuring the reliability of PFN1 antibody results:

• Genetic Controls:

  • Use PFN1 knockout cells (e.g., HAP1 PFN1 KO cells) as negative controls

  • Include rescue experiments with re-expression of PFN1 in knockout backgrounds

  • Compare results from siRNA/shRNA-mediated knockdown

• Antibody Validation Panel:

  • Test multiple antibodies targeting different epitopes of PFN1

  • Compare results from monoclonal and polyclonal antibodies

  • Validate antibody specificity through Western blot, showing a single band at the expected molecular weight (~15 kDa)

• Peptide Competition Assays:

  • Pre-incubate antibody with excess immunizing peptide

  • Compare signal with and without peptide competition

  • Specific signals should be significantly reduced or eliminated

• Recombinant Protein Standards:

  • Include purified recombinant PFN1 as a positive control

  • Create standard curves for quantification

  • Test antibody against recombinant PFN1 with mutations or tags to assess epitope sensitivity

• Orthogonal Detection Methods:

  • Confirm key findings using alternative techniques (e.g., mass spectrometry)

  • Correlate protein detection with mRNA expression data

  • Use tagged PFN1 constructs to correlate antibody signal with tag-specific detection

• Standardized Validation Protocol:

  • Follow the standardized experimental protocol described in search result , which includes parallel testing in wild-type and knockout systems

  • Document all validation experiments thoroughly

  • Include appropriate controls in every experiment

How can PFN1 antibodies be used to investigate neurodegenerative disease mechanisms?

PFN1 mutations have been identified in familial ALS patients, making it an important target for neurodegenerative disease research :

• Mutation-Specific Pathology:

  • Compare wild-type and mutant PFN1 aggregation patterns using immunofluorescence

  • Analyze differential binding to actin and other partners using co-immunoprecipitation

  • Assess effects on cytoskeletal organization through dual-staining with actin markers

• Motor Neuron Vulnerability:

  • Perform immunohistochemistry on spinal cord sections from ALS patients and controls

  • Quantify PFN1 expression levels in affected versus unaffected neuronal populations

  • Track progressive changes in PFN1 distribution during disease progression

• Cytoskeletal Dysfunction Analysis:

  • Investigate co-localization with other ALS-associated cytoskeletal proteins (TUBA4, ALS2, KIF5A, SPAST)

  • Measure alterations in actin dynamics in the presence of PFN1 mutations

  • Correlate cytoskeletal abnormalities with clinical phenotypes

• Therapeutic Target Validation:

  • Screen compounds for their ability to modulate mutant PFN1 aggregation

  • Assess effects of potential therapeutics on downstream cytoskeletal pathways

  • Monitor changes in PFN1-dependent signaling cascades during treatment

• Biomarker Development:

  • Evaluate PFN1 levels or post-translational modifications as potential biomarkers

  • Correlate PFN1 abnormalities with disease progression or treatment response

  • Develop assays for detecting pathological forms of PFN1 in accessible biofluids

What role does PFN1 play in cancer biology, and how can antibodies help elucidate these mechanisms?

PFN1 has been identified as a potential tumor suppressor, particularly in breast cancer . Antibody-based approaches can help uncover its roles in cancer:

• Tumor Suppressor Function:

  • Compare PFN1 expression levels across normal tissue, primary tumors, and metastases using immunohistochemistry

  • Correlate expression with clinical outcomes through tissue microarray analysis

  • Investigate mechanisms of PFN1 downregulation in cancer cells

• Signaling Pathway Modulation:

  • Study PFN1's effects on AKT signaling using phospho-specific antibodies for AKT (S473, T308) and downstream targets like GSK-3β

  • Investigate PTEN upregulation mechanisms using combined immunoprecipitation and Western blot approaches

  • Monitor phosphoinositide regulation through specialized antibody-based detection methods

• Cytoskeletal Reorganization in Metastasis:

  • Track changes in PFN1 localization during epithelial-mesenchymal transition

  • Analyze co-localization with invasion-associated cytoskeletal structures

  • Quantify effects of PFN1 modulation on cell migration and invasion

• Therapeutic Response Prediction:

  • Develop immunohistochemical scoring systems for PFN1 as a potential predictor of treatment response

  • Combine with other markers to create prognostic panels

  • Monitor dynamic changes during treatment using liquid biopsy approaches

• Concentration-Dependent Effects:

  • Investigate the dual role of PFN1 in actin polymerization (inhibitory at high concentrations, enhancing at low concentrations)

  • Determine threshold concentrations for these opposing effects in different cancer types

  • Correlate concentration-dependent functions with metastatic potential